Noteworthy, the GAD65 region 245-450 that includes both GAD65271-285 and GAD65431-450 has been identified as the main target of the earlier anti-GAD65 response in pre-diabetic, healthy high-risk subjects and early onset T1D patients (44–46). Here, GAD2 is linked to type 1 diabetes mellitus.